-
RLY-2608-201: A Phase 2 Study of Mutant-selective PI3Ka Inhibitor RLY-2608 in Adults and Children with PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
The purpose of this study is to learn about the safety and efficacy of RLY-2608 when given to individuals who have been diagnosed with PIK3CA ...Phase
Interventional
-
A Phase 2 Randomized Blinded Placebo Controlled Trial Investigating the Efficacy and Safety of Visugromab plus Nivolumab with or without Docetaxel versus Docetaxel Monotherapy in Second Line Treatment of Participants with Metastatic Non Squamous Non Small Cell Lung Cancer (GDFATHER NSCLC 02)
This is a Phase 2 study testing the drug visugromab (a GDF-15 neutralizing antibody) in people with non-squamous non-small cell lung cancer (NSCLC) who are ...
Phase
Interventional
-
A Phase 2 Open-label Study of VS-7375 an Oral KRAS G12D (ON/OFF) Inhibitor in Patients with Previously Treated Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)
This is a Phase II study for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called a KRAS G12D ...
Phase
Interventional
-
Physiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure: A Crossover Trial
This study is being conducted to evaluate if wearing a non-invasive breathing support device over the chest/abdomen improves markers of breathing in patients with ...Phase
Interventional
-
A Phase II Study of the Interferon Gamma Inhibitor Emapalumab for Prophylaxis of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients with Lymphoma and Multiple Myeloma Receiving Bispecific T-Cell Engagers.
This is a Phase 2, non-randomized study testing emapalumab, a medicine that blocks a protein called interferon gamma (IFN-y). The goal of this study is ...
Phase
Interventional
